AI-generated doctor content: where the review line sits
AI doctor content review is the set of rules deciding who must approve anything AI-assisted that carries a doctor’s name, face or voice. My line: the named doctor approves every piece in their name, clinical claims also go to a second clinical reviewer, synthetic voice or video needs explicit written consent, and some uses, such as generated patient replies under a doctor’s identity, should not happen at all.
A doctor’s name on a piece of content is a personal promise. It tells the reader that this specific person, with their training and registration, stands behind these words. Hospitals have always borrowed that promise for marketing, through bylined articles, quotes in press notes, social posts and video explainers. Mostly it worked because the doctor was involved in making the content, even if a writer did the drafting.
AI assistance quietly changes that arrangement. Drafts appear faster than doctors can read them. A model can write in a doctor’s style from their past articles. It can produce a script for a video, and increasingly it can produce the video, with a synthetic version of the doctor’s face and voice. Each step makes content cheaper and makes the doctor’s actual involvement thinner.
So the question every hospital marketing head now faces is where AI doctor content review has to sit. Who must see what, before it goes out under a doctor’s name. I have a clear view on this, and it is stricter than most teams would like.
Why doctor content is a different category
I have written about keeping medical accuracy intact when AI content scales. That piece is about the hospital’s own voice: condition pages, service explainers, FAQs. Doctor-attributed content raises a further set of problems on top of accuracy.
The first is attribution. When content is published as the hospital, the hospital is accountable. When it is published as a named doctor, the doctor’s personal professional reputation is on the line, and so is their standing with their peers and regulator. A doctor who did not really write or approve what appears under their name has been put at risk by the marketing team.
The second is trust. Patients read a doctor’s article differently from a hospital page. They assume personal expertise and personal judgement. If that assumption is false, the content is misleading even when every fact in it is correct.
The third is identity. Synthetic voice and video create a new kind of asset: a reusable likeness of a person. That likeness can outlive the doctor’s time at the hospital, be used in contexts they never saw, and be copied by others. None of those risks exist with an ordinary ghostwritten article.
A tiered view of doctor content
Not all doctor content carries the same risk, and a single rule for everything tends to be either too loose or too heavy to follow. I sort it into tiers based on two questions: how much the content says about clinical matters, and how directly it represents the doctor as a person.
The lowest tier is factual profile content. A doctor’s bio, qualifications, languages, consultation timings, areas of work. AI can help tidy and format this, and the doctor confirms it once, with updates when details change.
The next tier is event and logistics content in a doctor’s name. A post announcing a health camp the doctor is leading, a note about a public talk. Low clinical content, moderate personal representation. Doctor approval is still needed, but it is quick.
The middle tier is educational content attributed to the doctor: articles, social explainers, video scripts about a condition or procedure. High clinical content and high personal representation. This is where most volume sits and most risk accumulates.
The top tier is synthetic representation: any content that generates the doctor’s voice, face or conversational persona. This tier needs its own rules, discussed below, and some uses in it I would not allow at all.
Where the AI doctor content review line sits
Here is the line I would hold for the middle tier, where most of the real decisions happen.
Every AI-assisted piece published under a doctor’s name must be read and approved by that doctor, in its final form, before publication. Not the outline, not an earlier draft, the final text or the final cut of the video. A doctor approving an outline and then finding a different version live is the most common way this goes wrong.
Any piece that makes a clinical claim, describes outcomes, compares treatments or mentions risks goes to a second clinical reviewer as well, usually the head of department or someone the medical director nominates. Doctors are experts in their field, but they are also busy, and when they read a fluent draft they tend to skim. A second reader who did not commission the piece catches what the named doctor misses.
The draft must start from the doctor’s own input: an interview, notes, a recorded conversation, or a previous article they wrote and approved. A model writing “in the style of” a doctor on a topic they never discussed is not assistance. It is putting words in their mouth.
Within those limits, the model can do a lot of useful work. It can structure a rambling interview into a clear article, suggest headings, tighten sentences, draft a patient-friendly summary and propose social cut-downs of an approved piece. What it should not do is add facts, statistics, outcomes or recommendations that were not in the doctor’s input. I ask editors to treat any new factual sentence in an AI draft as unverified until it is traced back to the source or removed.
And the marketing editor remains accountable for everything that is not clinical: brand voice, claims about the hospital, legal compliance, consent for any patient references. Clinical approval does not replace editorial review. They check different things.
What the doctor is actually signing off
A sign-off is only as good as what the doctor understands they are approving. In practice, many approvals come as a quick “ok” on a messaging app between surgeries. That is not enough for AI-assisted content.
I ask for a short, standard approval note that the doctor confirms. It states that the doctor has read the final version, that the clinical content is accurate and within their own practice, that they are comfortable with it appearing under their name, and where it will appear. For video, the approval covers the final edit, not the script.
This is not bureaucracy for its own sake. It protects the doctor as much as the hospital. When a question is raised later about something published under their name, both sides can see exactly what was approved. It also makes the relationship healthier, which matters, because as I argued in the doctor as spokesperson, the doctor’s credibility is the asset, and marketing’s job is to protect it rather than spend it.
Translations and regional versions under a doctor’s name
Regional language content is where AI assistance is most useful and where the review line is most often broken without anyone noticing. A doctor approves an English article. The team then produces Hindi, Marathi, Tamil or Bengali versions with an AI assistant and publishes them under the same byline, on the assumption that approval carries over.
It does not. A translated article is a new piece of text. Medical terms shift, cautious phrasing can become confident, and a sentence that was careful in English can read as a promise in another language. If the named doctor does not read that language, their approval of the English version tells you nothing about the regional one.
My rule is that every language version needs a clinically literate reviewer who reads that language fluently, ideally a doctor from the same department. The named doctor should know which languages their content appears in and who reviewed each. Where no such reviewer exists, publish the regional version as hospital content rather than under the doctor’s name. It still reaches the audience, and it does not put words in a doctor’s mouth in a language they cannot check.
Synthetic voice and video: consent first
The fastest-moving area is synthetic media. Tools can now produce a video of a doctor explaining a procedure in several languages from a single recording, or clone a voice for audio content. The commercial appeal is obvious, especially for regional language reach.
My rules here are strict. Synthetic use of a doctor’s likeness or voice requires explicit, specific, written consent from the doctor, separate from their employment contract and separate from general content approvals. The consent should say what will be generated, in which languages, for which channels, for how long, and what happens to the voice or face model when the doctor leaves. The doctor approves every final synthetic output, just as with any other content. And the content should say it has been generated or translated, so that patients are not misled about what they are watching.
There are also uses I would refuse regardless of consent. A synthetic doctor answering individual patient questions in real time. A generated doctor persona responding to comments or messages. Anything that makes a patient believe they are receiving personal advice from a real clinician when they are not. These cross from marketing into something that looks like clinical care, and no marketing team should own that.
Social accounts, ghostwriting and the grey zone
Many hospitals help doctors run their own professional social media accounts. Some draft posts, some manage the accounts entirely. AI makes this much easier to scale, which is exactly why it needs rules.
My position is that a doctor’s personal professional account is theirs. The hospital can offer drafting help, including AI-assisted drafting from the doctor’s own input, but the doctor posts or explicitly approves each post. Replies to patients on those accounts should come from the doctor or not at all. A marketing executive using an AI assistant to reply to a patient’s question under a doctor’s name is the grey zone becoming a real problem.
Ghostwriting itself is not new or wrong. Doctors have always worked with writers. What changes with AI is volume and distance. The safeguard is the same one that worked before: the doctor’s thinking is the source, and the doctor approves the result.
Who owns the policy
This policy cannot belong to marketing alone. It touches clinical governance, legal, HR and the doctors themselves. In my experience, it works best when the medical director and the marketing head write it together and take it to the medical advisory committee or its equivalent. That is also the right forum to hear objections, and there will be some, usually from doctors who want less friction and a few who want no AI involvement at all.
That conversation is worth having openly. The approach in earning the right to change anything applies: doctors accept rules they helped shape. And it reinforces a point I make in doctors are important, the brand is bigger: the hospital’s reputation should not depend on any single doctor’s content, but it can certainly be damaged by it.
HR needs to be involved for one practical reason. When a doctor leaves, every piece of content in their name, and any synthetic asset of their voice or face, must be reviewed and in most cases retired. That has to be triggered by the exit process, not left to marketing to notice months later.
Drawing the line before the next draft
Start with an inventory. List every place doctor-attributed content appears: the website, the content hub, social accounts run by the hospital, doctors’ own accounts that marketing helps with, video channels, WhatsApp broadcasts. Note which items were AI-assisted, if anyone knows.
Then write a two-page policy with the medical director. The tiers, the review line for each, the approval note, the synthetic media consent and the uses you will not allow. Take it to the doctors, listen, adjust, and get it formally approved.
Set up the approval record at the same time. A simple log is enough: the piece, the channel, the language, the named doctor, the second reviewer where needed, the date of approval and whether AI assistance was used. It takes a minute per piece and saves hours of reconstruction the first time someone asks who approved a particular video.
Finally, apply it to what is already live. Some older content will not have a clear approval trail. For those pieces, ask the doctor to review now, and retire anything they would not stand behind. It is slower than publishing more. But every piece under a doctor’s name is either building trust in that doctor and the hospital or quietly borrowing against it, and the review line is how you know which.
Questions people ask
AI doctor content review is the set of rules deciding who must approve AI-assisted content that carries a doctor’s name, face or voice before it is published. It typically requires the named doctor to approve the final version, adds a second clinical reviewer for clinical claims, requires explicit consent for synthetic voice or video, and rules out certain uses entirely, such as generated replies to patients under a doctor’s identity.
It can be, if the doctor’s own input is the source and the doctor approves the final version. Ghostwriting has always existed in healthcare marketing, and AI mainly changes speed and volume. The problem arises when drafts are generated in a doctor’s style on topics they never discussed, or published without their review. Then the content misrepresents the doctor, even if the facts happen to be correct.
You are confirming that you have read the final version, that the clinical content is accurate and within your practice, and that you are comfortable with it appearing under your name in the stated channels. You are not responsible for brand voice or legal compliance about the hospital, which the marketing editor handles. Ask to see the final text or cut, not an outline or earlier draft.
Because busy doctors often skim fluent drafts, and AI-assisted text is fluent even when it is subtly wrong. A second clinical reader who did not commission the piece is more likely to catch overstatement, missing caveats or claims beyond the doctor’s practice. It is not a judgement on the named doctor. It is the same logic as any peer review, applied to content that patients will trust.
It should define content tiers, the review requirement for each, a standard approval note, the consent process for synthetic voice or video, and the uses the hospital will not allow. It should also require that content is retired or reviewed when a doctor leaves. The medical director and marketing head should write it together and take it through the medical advisory committee or equivalent.
Only with explicit, specific, written consent from the doctor, separate from their employment contract. The consent should state what will be generated, in which languages and channels, for how long, and what happens to the voice or face model when the doctor leaves. The doctor should approve every final output, and the content should be labelled as generated or translated so patients are not misled.
I would refuse any use where a synthetic or AI-generated doctor persona interacts with individual patients: answering questions in real time, replying to comments or messages, or giving anything resembling personal advice. These uses cross from marketing into something that looks like clinical care. No consent form makes that appropriate for a marketing team to run, and the risk to patients and to the doctor is too high.
The policy itself can be drafted in a few weeks. Getting it discussed and approved with doctors and the medical advisory committee usually takes longer, and that time is well spent because doctors accept rules they helped shape. Applying it to existing live content is the slowest part, since older pieces often lack clear approval records and need individual review.
Legal should review the synthetic media consent form, the standard approval note, and the rules about what happens to content and likeness assets when a doctor leaves. They should also advise on labelling generated content and on any regulatory expectations around medical professionals and advertising. Legal does not need to review each piece of content, only the framework and any unusual cases.
HR needs to connect doctor exits to content review. When a doctor leaves, every article, video, social post and synthetic asset in their name should be reviewed and usually retired. HR should also make sure synthetic media consent is handled separately from the employment contract, so that doctors do not feel it is a condition of employment and the consent is genuinely voluntary.
Yes, somewhat, especially at first. Doctor approval of final versions is the main constraint. But the volume that AI makes possible is not an asset if doctors cannot stand behind it. Planning content around the doctor’s real input, such as batching interviews, and giving doctors clear, quick approval notes reduces delays without cutting the review that protects them.
The risk is reputational and professional. Content under a doctor’s name that they did not really approve can damage the doctor’s standing, the hospital’s trust with patients and the relationship with its clinicians. A synthetic doctor used inappropriately could become a very public problem. The policy is inexpensive to put in place, and it is much easier to set before an incident than after one.
Agencies should follow the same policy as the in-house team: drafts start from the doctor’s input, the named doctor approves the final version, clinical claims get a second reviewer, and synthetic media needs documented consent. Ask agencies to disclose when AI assistance was used. The hospital, not the agency, should hold approval records and any consent documents.
A doctor’s professional account belongs to the doctor. The hospital can help with drafting, including AI-assisted drafts from the doctor’s input, but the doctor should post or explicitly approve each post. Replies to patients on those accounts should come from the doctor personally or not at all. Marketing staff using AI to respond under a doctor’s name is where real problems begin.
